ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,906.94
-1.07%
Dow Jones
42,573.73
-0.97%
US Dollar vs MXN
20.6599
0.06%
Brent Oil
74.345
0.33%
Bitcoin
92,321.25
-0.37%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Assertio Holdings Inc (ASRT) Cotización

Assertio Holdings Inc

Assertio Holdings Inc (ASRT)

BNP Paribas Asset Management Luxembourg
0.88
-0.0113
(-1.27%)
Cerrado 30 Diciembre 3:00PM
Delayed by 15 minutes
0.8612
-0.0188
(-2.14%)
Fuera de horario: 5:51PM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
0.8612
Postura de Compra
0.83
Postura de Venta
0.879
Volume Operado de la Acción
475,143
0.85 Rango del Día 0.889899
0.7324 Rango de 52 semanas 1.798
Capitalización de Mercado [m]
82.225M
Precio Anterior
0.8913
Precio de Apertura
0.874
Hora
4
@
0.879
Última hora de negociación
Volumen financiero
US$ 411,656
Precio Promedio Ponderado
0.866384
Volumen promedio (3 m)
763,229
Acciones en circulación
95,477,800
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.25
Beneficio por acción (BPA)
-3.48
turnover
152.07M
Beneficio neto
-331.94M

Acerca de Assertio Holdings Inc

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management... Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.assertiotx.com
Sede
Wilmington, Delaware, USA
Fundado
-
Assertio Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ASRT. The last closing price for Assertio was US$0.89. Over the last year, Assertio shares have traded in a share price range of US$ 0.7324 to US$ 1.798.

Assertio currently has 95,477,800 shares in issue. The market capitalisation of Assertio is US$85.10 million. Assertio has a price to earnings ratio (PE ratio) of -0.25.

ASRT Últimas noticias

Más noticias

Form 8-K - Current report

17 Diciembre 2024
Edgar (US Regulatory)

Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

17 Diciembre 2024
GlobeNewswire Inc.

Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study

LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

13 Diciembre 2024
GlobeNewswire Inc.

Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

LAKE FOREST, Ill., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

12 Diciembre 2024
GlobeNewswire Inc.

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced...

06 Diciembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

12 Noviembre 2024
Edgar (US Regulatory)

Assertio Reports Third Quarter 2024 Financial Results

Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million  Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE...

11 Noviembre 2024
GlobeNewswire Inc.

Assertio Provides Response to Letter from Short-seller

Claims about Rolvedon and Assertio’s Accounting Practices are False and Baseless Short-seller’s Press Release is Another Improper Attempt to Enrich Himself at Assertio’s Expense Company...

11 Noviembre 2024
GlobeNewswire Inc.

Assertio Holdings, Inc. to Report Third Quarter 2024 Financial Results on November 11, 2024

LAKE FOREST, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

30 Octubre 2024
GlobeNewswire Inc.

Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024

LAKE FOREST, Ill., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

11 Octubre 2024
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.00120.1395348837210.860.920.8414724000.87656545CS
4-0.1588-15.5686274511.021.07910.8188815820.92787237CS
12-0.2688-23.78761061951.131.160.787632290.94913702CS
26-0.3788-30.54838709681.241.7980.787849531.17698331CS
52-0.2188-20.25925925931.081.7980.73249135891.07531832CS
156-1.0288-54.43386243391.898.010.732412700483.18757152CS
260-0.5588-39.35211267611.428.010.3322239281.66408607CS

ASRT - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Assertio?
El precio actual de las acciones de Assertio es US$ 0.8612
¿Cuántas acciones de Assertio están en circulación?
Assertio tiene 95,477,800 acciones en circulación
¿Cuál es la capitalización de mercado de Assertio?
La capitalización de mercado de Assertio es USD 85.1M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Assertio?
Assertio ha negociado en un rango de US$ 0.7324 a US$ 1.798 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Assertio?
El ratio precio/beneficio de Assertio es -0.25
¿Cuál es el ratio de efectivo a ventas de Assertio?
El ratio de efectivo a ventas de Assertio es 0.55
¿Cuál es la moneda de reporte de Assertio?
Assertio presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Assertio?
El último ingresos anual de Assertio es USD 152.07M
¿Cuál es el último beneficio anual de Assertio?
El último beneficio anual de Assertio es USD -331.94M
¿Cuál es la dirección registrada de Assertio?
La dirección registrada de Assertio es 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
¿Cuál es la dirección del sitio web de Assertio?
La dirección del sitio web de Assertio es www.assertiotx.com
¿En qué sector industrial opera Assertio?
Assertio opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
WATTEnergous Corporation
US$ 2.70
(556.61%)
225.47M
NXUNXU Inc
US$ 1.52
(524.49%)
569.35M
HOLOMicroCloud Hologram Inc
US$ 6.40
(166.67%)
219.75M
INTZIntrusion Inc
US$ 5.67
(162.50%)
131.47M
SMXSMX Security Matters Public Company
US$ 0.803558
(127.25%)
370.01M
ICGIntchains Group Ltd
US$ 3.39
(-63.67%)
1.76M
ABPAbpro Holdings Inc
US$ 2.10
(-53.23%)
2.17M
LITMSnow Lake Resources Ltd
US$ 0.9212
(-42.43%)
68.48M
TRAWTraws Pharma Inc
US$ 8.33
(-37.93%)
1.18M
BDMDBaird Medical Investment Holdings Ltd
US$ 1.07
(-37.79%)
152.51k
NXUNXU Inc
US$ 1.52
(524.49%)
572.73M
SMXSMX Security Matters Public Company
US$ 0.803558
(127.25%)
370.63M
VINCVincerx Inc
US$ 0.3243
(67.16%)
335.59M
XTIAXTI Aerospace Inc
US$ 0.0395
(0.00%)
292.67M
WATTEnergous Corporation
US$ 2.70
(556.61%)
226.21M

ASRT Discussion

Ver más
dcaf7 dcaf7 2 semanas hace
Maxim Group analyst Naz Rahman has reiterated their bullish stance on ASRT stock, giving a Buy rating today.
Dec 16, 2024, 01:45 PM
Naz Rahman has given his Buy rating due to a combination of factors related to Assertio Therapeutics’ recent clinical study results. The same-day dosing study of Rolvedon, presented at the San Antonio Breast Cancer Symposium, demonstrated favorable outcomes for patients, including rapid recovery of neutrophil counts and a very low incidence of febrile neutropenia. This aligns well with the results from the Phase 3 trial, reinforcing the drug’s safety and efficacy profile.
Furthermore, there were no new safety concerns, and the adverse event profile remained consistent with previous trials. The potential for Rolvedon to be incorporated into the National Comprehensive Cancer Network guidelines could also boost its market penetration and sales growth. With these positive indicators, Rahman perceives significant sales potential for Rolvedon, contributing to the Buy rating for Assertio Therapeutics.
https://www.tipranks.com/news/blurbs/positive-clinical-results-and-market-potential-drive-buy-rating-for-assertio-therapeutics
👍️0
dcaf7 dcaf7 2 semanas hace
On Monday, H.C. Wainwright maintained its Buy rating and a price target of $4.00 for Assertio Therapeutics shares
The firm's stance follows Assertio Holdings' recent announcement of clinical trial results for ROLVEDON (eflapegrastim-xnst) injection. The trial focused on the drug's same-day dosing alongside chemotherapy in patients with early-stage breast cancer (ESBC).
The study, identified as NCT04187898, was an open-label, single-arm trial conducted at 13 U.S. sites. Participants were administered ROLVEDON 30 minutes after receiving chemotherapy for ESBC. Findings from the trial indicated a neutrophil count recovery time of 1.8 days and a febrile neutropenia rate of 2%.
The analyst from H.C. Wainwright highlighted the convenience and dosing flexibility of ROLVEDON, particularly its same-day dosing capability. This feature was seen as an incremental but potentially significant commercial differentiator.
https://www.investing.com/news/analyst-ratings/assertio-therapeutics-shares-get-buy-rating-on-clinical-trial-results-93CH-3774534
👍️0
dcaf7 dcaf7 2 semanas hace
End of same day dosing hype.
👍️0
ATLcitizen ATLcitizen 2 semanas hace
Now we have the PR.
👍️0
dcaf7 dcaf7 3 semanas hace
I think you know the answer.
👍️0
Grundle Grundle 3 semanas hace
So no chance of Rolvedon '24 (and 25) sales being more than 175m to pay out the CVR from Spectrum?
👍️0
KRISGO KRISGO 3 semanas hace
Here is ChatGPT comparing Rolvedon same day with Neulasta next day..
https://media.stocktwits-cdn.com/api/3/media/510403/medium.png
https://media.stocktwits-cdn.com/api/3/media/509105/medium.png
👍️0
dcaf7 dcaf7 4 semanas hace
If the data had been outstanding, the company would have issued a PR on Nov 25. No need to wait until Dec 13. Most importing findings are already described in the abstract. Actual presentation won't add much.
👍️ 1
KRISGO KRISGO 4 semanas hace
It looks like the company will be presenting these results at a conference on December 13th. The following message is from a poster named "D_S" on StockTwits.
"D_S: Nov 29, 2024 9:44 AM : $ASRT The abstract link showed back up again on the San Antonio Breast Conference website. ASRT's abstract is there. As such there is not an "embargo" on them releasing a pr. However, that pr can only discuss the abstract information, not fully discuss the research. It's part of the requirement to have research presented at this conference----they want the research discussed first there. So here is my opinion.....if same-day dosing results are only to be about the convenience of patients not having to go to a 2nd day visit, then ASRT puts out a simple pr on day of poster presentation (after market closes). If same-day dosing results are showing (as we think from analysis of abstract) that giving the infection on day of chemo reduces severe neutropenia vs next day dosing, then I think there could be chance of cc call (on top of pr) to discuss implications. CEO needs the stock price up to give him options for future large acquisition potentially, but at least to give investors confidence"
👍️0
dcaf7 dcaf7 4 semanas hace
The abstract is on SABCS website since Nov 25, 2024, not leaked. Data is OK, but Rolvedon won't be approved as same day injection. I don't think, it will boost sales much. Looks like market has same opinion. And ASRT doesn't even bother to issue a PR on these results.
👍️0
KRISGO KRISGO 4 semanas hace
I'm referring to the same-day dosing of Rovedon. The full abstract from ASRT has been leaked on San Antonio Breast Cancer Conference website, which is definitely positive news. It has the potential to boost sales and is gaining attention, but the stock doesn't seem to be moving upward. Any thoughts on why that is?
👍️0
dcaf7 dcaf7 4 semanas hace
Nothing really changed. Rolvedon doesn't look different from Neulasta and multiple biosimilars. Sales have remained flat over the last three quarters.
👍️0
dcaf7 dcaf7 4 semanas hace
REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company NASDAQ: CHRS,) today announced that it has entered into an asset purchase agreement (the Agreement) dated December 2, 2024, with Intas Pharmaceuticals Ltd. (Intas) for the divestiture of the UDENYCA (pegfilgrastim-cbqv) franchise for up to $558.4 million.
👍️0
KRISGO KRISGO 4 semanas hace
Hey guys, any idea why this stock isn't moving up? Rolvedon looks promising and definitely has long-term potential. The info seems to be out there, and the street is aware of it, but it’s not gaining any momentum. Any thoughts?
👍️0
KRISGO KRISGO 1 mes hace
got it, thanks dcaf7!
👍️0
dcaf7 dcaf7 1 mes hace
This trial was not design to demonstrate significant advantage. As you can read in the Conclusions, same day dosing "may be advantageous in reducing the time to ANC recovery". Just may be. This data will not result in label change, but it might be included in NCCN guidelines.
👍️0
KRISGO KRISGO 1 mes hace
dcaf7, thanks for sharing this. I'm not an expert in this area, so I'm not sure if this study offers a significant advantage over existing ones. What’s your take on it?
👍️0
dcaf7 dcaf7 1 mes hace
From the abstract
The primary endpoint was the time to recovery of absolute neutrophil counts (ANC) from nadir to ? 1.5×109/L in C1. Secondary endpoints included incidence of SN (ANC < 0.5×109/L) and FN (ANC < 1.0×109/L and temperature of > 38.3 oC or 2 consecutive readings ?
38.0 oC over 2 hours), duration of SN (DSN), and incidence of neutropenic complications, including use of antibiotics and/or hospitalizations.
Results: A total of 53 pts (mean [SD] age: 62.7 [11.9] years; female: 100%) from 13 sites across the US, were enrolled (White: 62.3%; Black or African American: 9.4%; others: 28.3%). Pts were relatively healthy (ECOG 0, 52.8% [n = 28] patients; ECOG 1, 47.2% [n =
25] patients). Efficacy in C1 was evaluable in 49 patients. Mean (SD) time to ANC recovery was 1.8 (1.1) days. Incidence of SN was 46.9% (n = 23) and mean (SD) DSN was 0.8 (1.0) days. Incidence of FN was 2% (n = 1). No neutropenic complications were observed during the study. Safety was assessed in all 53 patients who received at least 1 dose of eflapegrastim. Overall, 43 patients (81.1%) experienced any TEAE of musculoskeletal pain. Common musculoskeletal-related TEAEs experienced by ? 10% of patients were bone pain (52.8%; n = 28); back pain (26.4%; n = 14), arthralgia or pain in extremity (17.0%; n = 9 for each); and myalgia (13.2%; n = 7). No deaths were reported during the study.
Conclusions: These findings suggest that administration of eflapegrastim on the same day as TC chemotherapy may be advantageous in reducing the time to ANC recovery and related complications in pts with ESBC. The AEs observed in this study were consistent with those
generally observed in pts receiving TC and other GCSF products.
👍️ 1 🙏 1
KRISGO KRISGO 1 mes hace
Thanks dcaf7 🙏
👍️0
dcaf7 dcaf7 1 mes hace
They will get info about efficacy and safety but they won't be able to conclude whether this regimen works better or not.
👍️0
KRISGO KRISGO 1 mes hace
Hello Dcaf7, based on the full abstract being released on Nov 25th, can the experts evaluate whether same-day dosing is effective and works better?
👍️0
dcaf7 dcaf7 2 meses hace
Same day dosing data will be presented at SABCS meeting by Lee Schwartzberg on December 13, 2024.
Abstract title is "Eflapegrastim, a long-acting GCSF, administered the same day as chemotherapy in patients with early-stage breast cancer: Results from a multicenter, open-label, study". Full abstract release date is November 25, 2024.
👍️ 2
dcaf7 dcaf7 2 meses hace
On earning call, they said that SPRIX might become an important asset due to NONPAIN act.
The NOPAIN Act expands patient and provider access to FDA-approved non-opioids in all outpatient surgical settings beginning in 2025 by providing separate Medicare reimbursement for non-opioid therapies.
👍️ 1
dcaf7 dcaf7 6 meses hace
H.C. Wainwright starts Assertio at buy.
The investment bank said it believes Rolvedon could reach peak annual sales of around $140M in the early 2030s. It added that “long run positive traction” from products such as Rolvedon, Otrexup and Sympazan “ought to drive renewed interest from investors.”
The bank set its price target at $4.
👍️ 1
glenn1919 glenn1919 6 meses hace
ASRT.......................https://stockcharts.com/h-sc/ui?s=ASRT&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 6 meses hace
ASRT................................https://stockcharts.com/h-sc/ui?s=ASRT&p=W&b=5&g=0&id=p86431144783
👍️0
ATLcitizen ATLcitizen 7 meses hace
Heather Mason recently purchased 25K of ASRT shares.
👍️ 1
dcaf7 dcaf7 7 meses hace
A meta-analysis of the effect of pegfilgrastim biosimilars and eflapegrastim on DSN was presented at ASCO. "Additionally, eflapegrastim, another long-acting granulocyte-colony stimulating factor agent, significantly reduced DSN compared to conventional pegfilgrastim (WMD, n = –0.13 days; 95% CI –0.24 to –0.03; P = .01). The researchers recommended “exploring the impact of the drug in clinical settings on costs and patient-reported outcomes could provide valuable insights into optimizing the management of chemotherapy-related neutropenia.”
https://www.centerforbiosimilars.com/view/asco-2024-posters-showcase-positive-data-on-denosumab-pegfilgrastim-biosimilars
👍️ 1
Propain Propain 7 meses hace
bought some shares today. Gaurantee the stock will tumble now!
👍️0
dcaf7 dcaf7 8 meses hace
Rolvedon/eflapegrastim is a new molecule. You cannot call it "novel formulation". Novel formulation of what? Neulasta? Nonsense.
👍️ 1
ATLcitizen ATLcitizen 8 meses hace
dcaf7, please elaborate on what you mean?
👍️0
dcaf7 dcaf7 8 meses hace
Listened to yesterday ASRT presentation. They call Rolvedon a "novel formulation" (slide 5). Looks like these guys don't know what Rolvedon really is.
👍️ 1
dcaf7 dcaf7 9 meses hace
Rolvedon pediatric study is a postmarketing requirement from FDA. If it was up to Spectrum, they wouldn’t run it because of small commercial opportunity and approved Neulasta. I think completion of Phase 2 is what ASRT needs to accomplish. I doubt phase 3 will be required but they need to complete current study and to show the results to FDA that can happen 3-4 years away from now. As for Neulasta you can find that “no overall differences in safety were identified between adult and pediatric patients based on postmarketing surveillance”. As for same day dosing, I think, nobody knows what the next step looks like. Depends on data. Three years ago, JT said “If data is good, we would engage in a discussion with the FDA to path forward”. About a year ago, TR said the same, “whether that be going to chat with FDA about a regulatory path forward, whether it is publication, it is really contingent upon what we see in that data”.
👍️ 1
ATLcitizen ATLcitizen 9 meses hace
A couple questions. A few days ago, a phase 2 study showed pediatric patients tolerated Rolvedon without requiring dose reduction. I could not copy link, but can find on Stocktwits ASRT from poster Avedesian. What is the significance? Does this mean Assertio may market to pediatric patients now, or phase 3 required? Also, this poster says that Neulasta and biosimilars required dose reduction for pediatric patients. Does this mean R is safer? How does this differentiate R from Neulasta and biosimilars? Next question: Hanmi recently said in interview with a Korean biopharma news that they expect R to be successful in their same day dosing trial to get a 'competitive edge'. IMO this appears to be a sign that they will continue with another study if the current study is successful. Another poster on X, claiming to be a doctor (this was copied on Stocktwits) said that they expect it to be short study due to requiring only one cycle of treatment. Any ideas of how long to complete another study, including enrollment? Should this be a quicker study? TIA!
👍️0
glenn1919 glenn1919 10 meses hace
ASRT.........................https://stockcharts.com/h-sc/ui?s=ASRT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 10 meses hace
ASRT 10Q due March 11
👍️0
dcaf7 dcaf7 10 meses hace
I don’t have an answer about what does it mean. I can explain why they will finish it earlier. Because they reduced the number of patients from 90 to 50. Good sign is that trial is still enrolling. It means they think that a positive outcome is still possible. What is next if the data is good? In my opinion, for approval they need to conduct a larger trial. Not sure if they want it.
👍️ 1
ATLcitizen ATLcitizen 10 meses hace
The same day dosing trial for R has moved forward its study completion date from june 2025 to july 2024. Thoughts? Is this a good sign and if successful, what is next?
👍️0
dcaf7 dcaf7 11 meses hace
Hanmi Pharma said it has signed a strategic agreement with its U.S. partner company, Assertio Holdings, which previously acquired Spectrum Pharmaceuticals, to re-acquire the rights to Rolontis, a long-acting neutropenia treatment and Korea's 33rd novel drug, for the Asian and African markets.
Published 2024.02.02

?? : KBR(https://www.koreabiomed.com)
👍️ 1
Monksdream Monksdream 11 meses hace
ASRT new 52 week low
🌈 1 🍆 1 👎️ 1 🩳 1
dcaf7 dcaf7 1 año hace
What is interesting, Coherus said their injector is more patient friendly than what is used in Onpro. So, it looks like a competition of injectors now. Is it possible to win Neulasta market by introducing a better injector? Unexpected twist.
👍️ 1
ATLcitizen ATLcitizen 1 año hace
Good question, dcaf7!
👍️0
dcaf7 dcaf7 1 año hace
Shares of Coherus BioSciences (NASDAQ:CHRS) surged 36.4% after the FDA had approved an on-body injector version of the biosimilar – Udenyca for post-chemotherapy treatment Neulasta.
https://seekingalpha.com/news/4050413-biggest-stock-movers-today-coherus-biosciences-bit-digital
It will make more difficult for Rolvedon to compete. Why Spectrum or Assertio didn't start on-body injector program in addition to same day dosing?
👍️0
dcaf7 dcaf7 1 año hace
Hi ATLcitizen! Good to see you here. I think physicians view Ryzneuta the same way as Rolvedon. No clear differentiation from Neulasta. Assertio should work on same day dosing. As for Poziotinib, I don't know. I don't see any new trials with Pozi but I see several drug candidates in development that are less toxic. I found interesting document describing what exactly Spectrum did to be acquired. It looks like Hanmi was considering to buy Spectrum.
https://www.sec.gov/Archives/edgar/data/1808665/000110465923071264/tm2315184-6_s4a.htm
This acquisition story is described on pp71-82 step by step. Board was interested to sell the company when TR became a CEO. "Following the appointment of Thomas J. Riga as Spectrum’s President and Chief Executive Officer effective January 1, 2022, the Spectrum board of directors engaged in discussions regarding potential strategic alternatives at each of its regularly scheduled meetings and authorized Mr. Riga and the Spectrum management team to explore potential strategic alternatives".
👍️ 1
ATLcitizen ATLcitizen 1 año hace
What a shocker. I thought Pozi was dead. What do you think Hanmi is trying to do- get approval for 3rd line treatment? What about the whole dosing and side effects problem that FDA issued a CRL for--is Hanmi addressing that as far as you know? Do you know if MDA is still interested in investigating Pozi or have moved on? TIA.
👍️0
ATLcitizen ATLcitizen 1 año hace
Hi dcaf7! Found you again! What do you think of Ryzneuta?
👍️0
dcaf7 dcaf7 1 año hace
Ryzneuta was approved 3 weeks ago. Second "novel" long-acting G-CSF. Acrotech is going to market it in the US. It is same company that markets five Spectrum drugs.
https://acrotechbiopharma.com/wp-content/uploads/2023/11/Evive-and-Acrotech-Announce-FDA-Approval-of-Ryzneuta.pdf
👍️ 1
dcaf7 dcaf7 1 año hace
On Hanmi. Brokerages raise stock price targets for Korean traditional pharma citing licensing deals, export gains.
Daishin Securities set the target prices for Hanmi Pharm and Yuhan Corp. from the current 315,500 won and 63,300 won to 420,000 won and 92,000 won, respectively. Hanmi has strengths in the continued steady profit growth through the sales of key products like Rosuzet, Amozaltan family, and Rolvedon.
👍️0
dcaf7 dcaf7 1 año hace
Hanmi is ready to conduct a Phase 4 study "Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy (NEUTHREE)". Title is misleading since they are using Eflapegrastim (Rolvedon), not Pegfilgrastim (Neulasta). You can see it in official title, "Reducing Neutropenia Incidence by Changing the Date of Eflapegrastim Administration in Breast Cancer Patients Who Have Experienced Neutropenia After Chemotherapy". Here is a rationale for this study, "It is known that patients who experience neutropenia after the first round of chemotherapy are more likely to experience it again in subsequent rounds. The investigators aimed to see whether changing the pegfilgrastim administration date from day 1 to day 3 starting from the second round of chemotherapy for patients who experienced neutropenia after receiving pegfilgrastim on day 1 of the first round can reduce the incidence of neutropenia".
https://classic.clinicaltrials.gov/ct2/show/NCT05949333?term=eflapegrastim&draw=2&rank=2
👍️ 1
Johnny R Johnny R 1 año hace
very disappointing earnings release . . . . and the insiders all sold their stock to cover taxes on their options . . . . sure, whatever you say
👍️0

Su Consulta Reciente

NASDAQ
ASRT
Assertio
BOV
UPAC34
UnionPacific
NASDAQ
CRDO
Credo Technology
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados